Press releases

* (R) = Regulatory press releases

Aug 14, 2023

Invitation to presentation of Cantargia’s report for the first half of 2023 on August 22 at 3.00 p.m. CEST
Aug 10, 2023

(R) Cantargia receives regulatory approval to start phase I clinical trial for CAN10
Jul 5, 2023

(R) Cantargia reports favorable outcome of patent oppositions in Europe
Jun 4, 2023

Cantargia publishes ASCO 2023 poster on promising nadunolimab efficacy in non-small cell lung cancer
Jun 1, 2023

(R) Cantargia announces updates to the management team
May 25, 2023

(R) Cantargia to present promising nadunolimab efficacy in non-small cell lung cancer at ASCO 2023, including two complete responses
May 23, 2023

(R) Annual General Meeting in Cantargia AB (publ)
May 23, 2023

(R) Cantargia publishes interim report for the first quarter of 2023
May 15, 2023

(R) Cantargia intensifies development of nadunolimab in pancreatic cancer with new controlled phase IIb clinical trial following strong phase IIa efficacy results
May 9, 2023

Invitation to presentation of Cantargia’s report for the first quarter of 2023 on May 23 at 10.00 a.m. CEST
<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB